H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Denali Therapeutics to $95 from $105 and keeps a Buy rating on the shares. Given the DNL788 did not meet the primary endpoint in amyotrophic lateral sclerosis patients, the firm reflected the same in the stock’s valuation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DNLI:
- Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
- Denali Therapeutics Strengthens R&D with $500M Investment
- Denali Therapeutics Announces $500 million Private Placement Equity Financing
- Denali Therapeutics (DNLI) Q4 Earnings Cheat Sheet
- Denali Therapeutics’ treatment of MPS IIIA granted FDA orphan designation
